The Hill News

For the past two decades (the PSA screening era), we have seen a nearly 40 percent decrease in deaths from prostate cancer although there has been no increase in incidence during this interval. This month, a follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC) was published in the New England Journal of Medicine. It confirmed what urologists and other health care providers have known for years: PSA screening is a valuable life-saving tool. The study, “Prostate-Cancer Mortality at 11 Years of Follow-up,” showed that the statistical significance of prostate screening for all age groups has improved, with an overall survival advantage of 21 percent. More importantly, for patients followed for more than 10 years, this advantage increased to 38 percent.

Read more...